[1,2,4]Triazolo[1,5-a]Pyridine JAK Inhibitors for JAK1/TYK2 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for JAK kinase-related autoimmune, inflammatory, allergic, and graft-versus-host diseases are inadequate, particularly in conditions like inflammatory bowel disease, allergic dermatitis, psoriasis, systemic lupus erythematosus, and graft-versus-host disease, necessitating the development of more effective JAK inhibitors.
Innovation Solution
The development of [1,2,4]triazolo[1,5-a]pyridine compounds and their isomers or pharmaceutically acceptable salts as JAK inhibitors, which demonstrate selective inhibition of JAK1 and/or TYK2, showing efficacy in treating these diseases through in vitro and in vivo animal model tests.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing JAK inhibitors are used for treatment, then some therapeutic effect is achieved, but the efficacy is insufficient and side effects occur
Solution Approach 1:
The patent applies local quality by designing JAK inhibitors with selective inhibition profiles for specific JAK isoforms (JAK1, JAK2, JAK3, TYK2) rather than non-selective inhibition. This selectivity allows the drug to target pathological JAK signaling in autoimmune and inflammatory diseases while sparing physiological JAK functions, thereby improving therapeutic efficacy and reducing side effects simultaneously
Solution Approach 2:
The patent employs parameter changes by optimizing the chemical structure of JAK inhibitors (using [1,2,4]triazolo[1,5-a]pyridine core with various substituents) to achieve desired binding affinity and selectivity parameters. By adjusting molecular parameters such as substituent groups (R1-R6), the drug's potency and selectivity are tuned to maximize therapeutic effect while minimizing off-target effects
2Measurement precision
If JAK inhibitors are developed for selective inhibition, then therapeutic precision is improved, but drug development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the JAK inhibitor development into systematic stages: identifying the core [1,2,4]triazolo[1,5-a]pyridine structure, then systematically varying substituent groups (R1-R6) to achieve different selectivity profiles. This segmented approach to molecular optimization allows for methodical achievement of selectivity while managing development complexity through structured chemical space exploration
Data Source
AI summary
Disclosed is the use of a JAK inhibitor [1,2,4]-triazolo-[1,5-a]0pyridine compound in the preparation of drugs for treating autoimmune, inflammatory or allergic diseases, or diseases such as transplant rejection. The JAK inhibitor [1,2,4]-triazolo-[1,5-a]-pyridine compound comprises a compound as shown in formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof. The JAK inhibitor has a good efficacy in animal model tests of diseases such as autoimmune, inflammatory or allergic diseases.